PB-vcMMAE-5 / Precision Biologics - LARVOL DELTA

Precision Biologics to Reveal Preclinical Efficacy of Novel Tumor-Specific ADC against multiple human cancer types at SITC 2025 (PRNewswire) - "PB-223 strongly reacted with colorectal, pancreatic, lung, prostate, and ovarian tumor tissues....This study shows that PB-vcMMAE-5 effectively killed all cell lines tested, with the highest percentage of killing observed against MDA-MB-231 (triple negative breast), LnCAP (prostate), OV-90 (ovarian), and NCI-H226 (lung) cancer cell lines....The ADC PB-vcMMAE-5 was well tolerated in mice. No sign of distress and no loss of body weight were observed."

Preclinical • Colorectal Cancer • Non Small Cell Lung Cancer • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Triple Negative Breast Cancer

In vitro and in vivo efficacy of the antibody-drug-conjugate (ADC) PB-vcMMAE-5 against human carcinoma expressing truncated core 2 O-glycans (SITC 2025) - "PB-223 was created through affinity maturation of NEO-102, a chimeric human IgG1 mAb that targets tumor specific truncated core-2 O-glycans. A dose escalation study of 1,3,6, and 9 mg/kg is ongoing. These findings support its potential as broad-spectrum therapeutic agent against tumors expressing truncated core 2 O-glycans."

Preclinical • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PGR

Precision Biologics to Present Recent Data on a New Antibody-Drug Conjugate (ADC) Utilizing the Monoclonal Antibody (mAb) PB-223, at AACR Annual Meeting 2025 (PRNewswire) - "Precision Biologics, Inc. reports preclinical development and characterization of a novel ADC using its anti-core 2 O-glycans anti-human carcinoma mAb PB-223 will be presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2025, on April 29th, 2025....We evaluated the ability of all three ADC clones to kill OV-90 cells. All three ADCs effectively killed OV-90 cells (80% of cells were dead 5 days after treatment). We then chose one ADC clone, PB-MMAE-5, to test its ability to kill additional human cancer cell lines. Preliminary results show that PB-MMAE-5 can kill human prostate, triple positive and triple negative breast, lung, colon, pancreatic cancer cell lines."

Preclinical • Colon Cancer • Lung Cancer • Pancreatic Cancer • Prostate Cancer • Triple Negative Breast Cancer